文献速递神经核医学

帕金森病左旋多巴诱导运动障碍与纹状体感觉运动亚区多巴胺能耗竭相关

Levodopa-Induced Dyskinesia in Parkinson Disease Specifically Associates With Dopaminergic Depletion in Sensorimotor-Related Functional Subregions of the Striatum.
PubMed 文献 · Clin Nucl Med · 2021-01-01

本研究在185例本土招募的帕金森病患者(73例,40%出现左旋多巴诱导运动障碍)中,利用123I-FP-CIT SPECT量化纹状体功能亚区多巴胺转运体结合比,发现左旋多巴诱导运动障碍患者的感觉运动亚区多巴胺转运体水平降低最显著(F=5.99,P=0.016),执行亚区也显著(F=5.30,P=0.023)。在帕金森进展标志物计划队列的343例初治患者中验证,左旋多巴诱导运动障碍患者(161例,47%)仅在感觉运动亚区多巴胺转运体水平显著降低(t=-2.05,P=0.041),且该差异在基线即存在并随时间保持稳定。

要点

  • 左旋多巴诱导运动障碍与纹状体感觉运动亚区多巴胺转运体耗竭特异性相关。
  • 执行亚区多巴胺转运体降低也在本土队列中与左旋多巴诱导运动障碍相关。
  • 感觉运动亚区多巴胺转运体差异在早期初治患者基线即出现并保持稳定。

核心结论

  • 测量功能定义的感觉运动相关纹状体感兴趣区的多巴胺转运体耗竭,可能更敏感地检测早期疾病阶段左旋多巴诱导运动障碍相关的多巴胺能变化,并改善对该常见临床并发症的个体化预后判断。

研究设计与样本

  • 主要研究样本为185例本土招募的帕金森病患者,其中73例(40%)出现左旋多巴诱导运动障碍,采用回顾性123I-FP-CIT SPECT数据量化纹状体功能亚区多巴胺转运体结合比。
  • 验证队列为帕金森进展标志物计划中343例初治帕金森病患者的系列123I-FP-CIT SPECT数据,采用混合线性模型分析。

主要发现

  • 在本土队列中,与未出现左旋多巴诱导运动障碍的患者相比,出现左旋多巴诱导运动障碍的患者多巴胺转运体水平降低在感觉运动纹状体亚区最显著(F=5.99,P=0.016),在执行相关亚区也显著(F=5.30,P=0.023)。
  • 在帕金森进展标志物计划队列中,出现左旋多巴诱导运动障碍的患者(n=161,47%)仅在感觉运动纹状体亚区多巴胺转运体水平较未出现者显著降低(t=-2.05,P=0.041)。
  • 在帕金森进展标志物计划队列中,感觉运动纹状体亚区的多巴胺转运体差异在基线时即已存在,并随时间基本保持恒定。

临床怎么用

  • 可利用123I-FP-CIT SPECT测量功能定义的感觉运动相关纹状体亚区多巴胺转运体耗竭,辅助早期识别左旋多巴诱导运动障碍高风险患者并改善个体化预后判断。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To determine whether the development of levodopa-induced dyskinesia (LID) in Parkinson disease (PD) specifically relates to dopaminergic depletion in sensorimotor-related subregions of the striatum. METHODS: Our primary study sample consisted of 185 locally recruited PD patients, of which 73 (40%) developed LID. Retrospective 123I-FP-CIT SPECT data were used to quantify the specific dopamine transporter (DAT) binding ratio within distinct functionally defined striatal subregions related to limbic, executive, and sensorimotor systems. Regional DAT levels were contrasted between patients who developed LID (PD + LID) and those who did not (PD-LID) using analysis of covariance models controlled for demographic and clinical features. For validation of the findings and assessment of the evolution of LID-associated DAT changes from an early disease stage, we also studied serial 123I-FP-CIT SPECT data from 343 de novo PD patients enrolled in the Parkinson Progression Marker's Initiative using mixed linear model analysis. RESULTS: Compared with PD-LID, DAT level reductions in PD + LID patients were most pronounced in the sensorimotor striatal subregion (F = 5.99, P = 0.016) and also significant in the executive-related subregion (F = 5.30, P = 0.023). In the Parkinson Progression Marker's Initiative cohort, DAT levels in PD + LID (n = 161, 47%) were only significantly reduced compared with PD-LID in the sensorimotor striatal subregion (t = -2.05, P = 0.041), and this difference was already present at baseline and remained largely constant over time. CONCLUSION: Measuring DAT depletion in functionally defined sensorimotor-related striatal regions of interest may provide a more sensitive tool to detect LID-associated dopaminergic changes at an early disease stage and could improve individual prognosis of this common clinical complication in PD.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Labrador-Espinosa MA, Grothe MJ, Macías-García D, et al. Levodopa-Induced Dyskinesia in Parkinson Disease Specifically Associates With Dopaminergic Depletion in Sensorimotor-Related Functional Subregions of the Striatum. Clin Nucl Med. 2021. PMID: 33782308. doi:10.1097/RLU.0000000000003609

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。